18 results
8-K
EX-99.1
PRAX
Praxis Precision Medicines Inc
7 Nov 23
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2023 Financial Results
7:35am
patients engaged in pre-recruitment observational study
Elsunersen EMBRAVE study final dose completed, Praxis seeking FDA advice on advancing development … mg dose of ulixacaltamide for up to 12 weeks after a short titration period. In September 2023, Praxis initiated a pre-recruitment observational
8-K
EX-99.1
PRAX
Praxis Precision Medicines Inc
13 May 24
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2024 Financial Results
8:18am
investigating PRAX-628 in focal onset seizures in the second half of 2024 and first half of 2025, respectively
Continued strong recruitment for the pivotal … a 12-week, parallel design study and a 12-week randomized withdrawal study for stable responders.
oSince beginning recruitment in November 2023
8-K
EX-99.1
PRAX
Praxis Precision Medicines Inc
16 Aug 21
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2021 Financial Results
8:04am
-944 Phase 2a trial for treatment of ET, assessing patients titrated up to 120 mg/day of PRAX-944. Due to delays in recruitment in Australia
8-K
EX-99.1
PRAX
Praxis Precision Medicines Inc
5 Mar 24
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
7:13am
).
oEssential3 has over 3,000 referrals who have met the pre-qualifying eligibility criteria from the ongoing recruitment campaign started in November 2023
8-K
EX-99.2
PRAX
Praxis Precision Medicines Inc
5 Mar 24
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
7:13am
TETRAS ADL* scale
11 Alignment with FDA on dose and primary endpoint Phase 3 program design structured around the patient needs Robust recruitment
DEF 14A
8y4u6
29 Apr 21
Definitive proxy
4:04pm
DRS
s125esp262alpf31ud
22 Jul 20
Draft registration statement
12:00am
S-1/A
6kus9wreduuqg
9 Oct 20
IPO registration (amended)
6:09am
424B4
rtt41hqmx1 i0whwd3
16 Oct 20
Prospectus supplement with pricing info
4:02pm
DRS/A
4jtiaq vse
28 Aug 20
Draft registration statement (amended)
12:00am
S-1
a51b5ks5tc3udo6it
25 Sep 20
IPO registration
5:19pm
10-Q
m4p2zvrqru
23 Nov 20
Quarterly report
4:16pm
10-K
zraf18dvd9t fbg
17 Mar 21
Annual report
8:33am
- Prev
- 1
- Next